NMPA Accepts Bio-Thera Solution's BLA for BAT2206, a Proposed #Biosimilar to Stelara (ustekinumab) #biosimilars #crohns #psoriasis #arthritis #ulcerativecolitis bio-thera.com/plus/view.php?…

Bio-Thera Solutions Announces the Launch of TOFIDENCE™ (tocilizumab-bavi) in the United States #biosimilars #arthritis #biosimilar bio-thera.com/plus/view.php?…

Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab #Biosimilar, in the EU and UK #biosimilars #arthritis prnewswire.com/news-releases/…

#ASCO #ADC #ovariancancer #ASCO24 #oncology #cancer #tumor #folatereceptor #bystandereffect #ASCO2024

Bio-Thera Solutions (Bio-Thera Solutions) and Biogen (Biogen) Publish Phase 3 Clinical Trial Data for TOFIDENCE™ (BAT1806/BIIB800), an approved #Biosimilar referencing tocilizumab in Arthritis Research & Therapy #biosimilars #arthritis #phase3 prnewswire.com/news-releases/…

Bio-Thera Solutions signs biosimilars deal with Gedeon Richter thepharmaletter.com/bio-thera-sign…

First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders --- onlinelibrary.wiley.com/doi/10.1111/cn… #CD20 #autoimmune #ophthalmology #raredisease

Bio-Thera Solutions (Bio-Thera Solutions) Expands Partnership with SteinCares in LATAM with Addition of a Third #Biosimilar to Partnership #LATAM #biosimilars prnewswire.com/news-releases/…

Bio-Thera Solutions (Bio-Thera Solutions) Partners with Tabuk Pharmaceuticals (Tabuk Pharma) to Commercialize BAT2206, a Stelara® (Ustekinumab) #Biosimilar in Saudi Arabia #autoimmune #Crohns #ulcerativecolitis #inflammation #biosimilars prnewswire.com/news-releases/…

Bio-Thera Announces Promising Phase I Results for BAT4406F in Patients with Neuromyelitis Optica Spectrum Disorders - Check the Link for More shorturl.at/hFFJK Bio-Thera Solutions #NMOSD #RareDiseases #OrphanDrugs #MedicalResearch #NeuromyelitisOptica #DrugDevelopment

Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed #Biosimilar Referencing Simponi® (#golimumab), in the United States of America #biosimilars #Simponi #TNF #arthritis prnewswire.com/news-releases/…

Proud to add another biosimilar asset to our pipeline! Our parent company Intas Pharmaceuticals, Ltd. signed an exclusive commercialization and licensing agreement with Bio-Thera Solutions for BAT2506, a golimumab biosimilar candidate. We look forward to next steps as we continue

Bio-Thera Solutions and Dr. Reddy’s Laboratories Ltd sign biosimilars deal thepharmaletter.com/biosimilars/bi…

🔎 Experts discuss recent FDA approvals affecting dermatology: -       Starjemza (Bio-Thera Solutions) -       Zoryve (Arcutis Biotherapeutics) -       Yuflyma (Celltrion) -       Dupixent (Sanofi and Regeneron) -       Keytruda (Merck) healio.com/news/dermatolo… Douglas Adkins Healio

IDMC Provides Positive Recommendation for Bio-Thera Solution’s BAT4406F in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Phase II/III Trial - For More Information Visit shorturl.at/bAGXW Bio-Thera Solutions #Neuromyelitis_Optica #NMOSD #Rare_Diseases

Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed #Biosimilar to Simponi® #biosimilars #arthritis #psorasis #TNFalpha #BLA #golimumab #simponi prnewswire.com/news-releases/…

Bio-Thera Solutions Receives Positive CHMP Opinion for USYMRO®(ustekinumab), a #Biosimilar Referencing Stelara® #biosimilars #psoriasis #arthritis #crohns #ulcerativecolitis prnewswire.com/news-releases/…

IDMC Provides Positive Recommendation for Bio-Thera Solution's BAT4406F (ADCC-Enhanced Anti-#CD20 mAb) in Neuromyelitis Optica Spectrum Disorder Based on Interim Analysis of Pivotal Phase II/III Trial #NMOSD #RareDisease #Phase3 #ophthalmology #autoimmune prnewswire.com/news-releases/…

Bio-Thera and STADA Extend #Biosimilars Alliance to Tocilizumab #biosimilar #arthritis #Actemra #EuropeanUnion #UK #Switzerland #MENA #CIS prnewswire.com/news-releases/…

Medicines and Healthcare products Regulatory Agency (MHRA) Approves Bio-Thera Solutions’ Qletli® (adalimumab), a #biosimilar referencing Humira® #biosimilars #arthritis #psoriasis #crohnsdisease #UC bio-thera.com/plus/view.php?…